University of Alabama at Birmingham Birmingham United States
Since the last annual report, we have continued with periodic advertising, recruitment, participant screening, participant enrollment, and the study protocol. All start up subtasks have been completed. The study treatment compounds have been purchased, and the blinded capsules have been created and prepared into randomized lines. To date, 222 potential participants have filled out the online screening questionnaire, 129 of those have been screened by telephone, and 34 participants have enrolled into the study, and 3 have re-enrolled. 5 other potential participants have been identified as meeting initial eligibility requirements, and we expect to meet our end goal number during the next reporting period. We have been approved to enroll participants with diabetes.